ONCS

OncoSec Medical Stock Price

5.17
-0.26 (-4.79%)
Upgrade to Real-Time
Afterhours (Closed)
5.17
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
OncoSec Medical Incorporated ONCS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.26 -4.79% 5.17 00:00:08
Open Price Low Price High Price Close Price Prev Close
5.43 5.12 5.55 5.17 5.43
Bid Price Ask Price Spread News
1.40 7.37 5.97 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,110 159,759 $ 5.31 $ 847,665 362,404 1.40 - 8.1598
Last Trade Time Type Quantity Stock Price Currency
16:00:00 2,366 $ 5.17 USD

OncoSec Medical Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 144.71M 27.99M 15.87M $ - $ - -2.89 -2.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

OncoSec Medical News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ONCS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week5.155.555.055.28173,1450.020.39%
1 Month5.506.284.455.39170,026-0.33-6.0%
3 Months6.338.15984.456.45309,488-1.16-18.33%
6 Months3.708.15983.355.86288,0391.4739.73%
1 Year1.598.15981.404.34309,8573.58225.16%
3 Years20.7021.001.039.16546,473-15.53-75.02%
5 Years23.9034.901.0312.88581,578-18.73-78.37%

OncoSec Medical Description

OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.


Your Recent History
NASDAQ
ONCS
OncoSec Me..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.